Potential for bone turnover markers to cost-effectively identify and select post-menopausal osteopenic women at high risk of fracture for bisphosphonate therapy

Osteoporosis International

Volumn 18, Issue 2, 2007, Pages 201-210

  Schousboe, J T ^a,b   Bauer, D C ^c   Nyman, J A ^b   Kane, R L ^b,d   Melton, L J ^e   Ensrud, K E ^b,f  

^a PARK NICOLLET INSTITUTE   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e MAYO CLINIC   (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Bisphosphonates; Bone turnover; Cost effectiveness; Non vertebral fracture; Vertebral fracture

Indexed keywords

ALENDRONIC ACID; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE;

ARTICLE; BONE TURNOVER; COST EFFECTIVENESS ANALYSIS; FRAGILITY FRACTURE; HIGH RISK POPULATION; OSTEOPENIA; PATIENT IDENTIFICATION; PATIENT SELECTION; POSTMENOPAUSE; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; RISK REDUCTION; SCORING SYSTEM; STATISTICAL MODEL;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ALENDRONATE; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES, METABOLIC; COST-BENEFIT ANALYSIS; DIPHOSPHONATES; FEMALE; FRACTURES, BONE; HUMANS; MARKOV CHAINS; MIDDLE AGED; POSTMENOPAUSE; QUALITY-ADJUSTED LIFE YEARS; RISK FACTORS; SPINAL FRACTURES;

EID: 33846124899     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-006-0218-7     Document Type: Article

References (47)

1. Melton LJ III (2003) Adverse outcomes of osteoporotic fractures in the general population. J Bone Miner Res 18(6):1139-1141
2. Black DM, Thompson DE, Bauer DC et al (2000) Fracture risk reduction with alendronate in women with osteoporosis: the fracture intervention trial. FIT Research Group. J Clin Endocrinol Metab 85(11):4118-4124
3. Wainwright SA, Marshall LM, Ensrud KE et al (2005) Hip fracture in women without osteoporosis. J Clin Endocrinol Metab 90(5):2787-2793
4. Siris ES, Miller PD, Barrett-Connor E et al (2001) Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA 286(22):2815-2822
5. Schousboe JT, Nyman JA, Kane RL et al (2005) Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women. Ann Intern Med 142(9):734-741
6. Ross PD, Kress BC, Parson RE, Wasnich RD et al (2000) Serum bone alkaline phosphatase and calcaneus bone density predict fractures: a prospective study. Osteoporos Int 11(1):76-82
7. Robbins JA, Schott AM, Garnero P et al (2005) Risk factors for hip fracture in women with high BMD: EPIDOS study. Osteoporos Int 16(2):149-154
8. Chapurlat RD, Garnero P, Breart G et al (2000) Serum type I collagen breakdown product (serum CTX) predicts hip fracture risk in elderly women: the EPIDOS study. Bone 27(2):283-286
9. Garnero P, Hausherr E, Chapuy MC et al (1996) Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res 11(10):1531-1538
10. Garnero P, Sornay-Rendu E, Claustrat B et al (2000) Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res 15(8):1526-1536. Aug 2000
11. Gerdhem P, Ivaska KK, Alatalo SL et al (2004) Biochemical markers of bone metabolism and prediction of fracture in elderly women. J Bone Miner Res 19(3):386-393
12. Sonnenberg FA, Beck JR (1993)Markov models in medical decision making: a practical guide. Med Decis Making 13(4):322-338
13. Melton LJ III, Crowson CS, O'Fallon WM (1999) Fracture incidence in Olmsted County, Minnesota: comparison of urban with rural rates and changes in urban rates over time. Osteoporos Int 9(1):29-37
14. Melton LJ III (1996) History of the Rochester epidemiology project. Mayo Clin Proc 71(3):266-274
15. De Laet CE, van Hout BA, Burger H et al (1997) Bone density and risk of hip fracture in men and women: cross sectional analysis. BMJ 315(7102):221-225
16. Looker AC, Wahner HW, Dunn WL et al (1998) Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int 8(5):468-489
17. Marshall D, Johnell O, Wedel H (1996) Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312(7041):1254-1259
18. Black DM, Arden NK, Palermo L et al (1999) Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. Study of Osteoporotic Fractures Research Group. J Bone Miner Res 14(5):821-828
19. Melton LJ III, Ilstrup DM, Beckenbaugh RD et al (1982) Hip fracture recurrence. A population-based study. Clin Orthop 167:131-138
20. Cuddihy MT, Gabriel SE, Crowson CS et al (1999) Forearm fractures as predictors of subsequent osteoporotic fractures. Osteoporos Int 9(6):469-475
21. Cummings SR, Black DM, Thompson DE et al (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the fracture intervention trial. JAMA 280(24):2077-2082
22. Quandt SA, Thompson DE, Schneider DL et al (2005) Effect of alendronate on vertebral fracture risk in women with bone mineral density T scores of-1.6 to -2.5 at the femoral neck: the fracture intervention trial. Mayo Clin Proc 80(3):343-349
23. Bauer DC, Garnero P, Hochberg MC et al (2006) Pre-treatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial. J Bone Miner Res 21(2):292-299
24. Tosteson AN, Jonsson B, Grima DT et al (2001) Challenges for model-based economic evaluations of postmenopausal osteoporosis interventions. Osteoporos Int 12(10):849-857
25. United States Life Tables for 1999 (2002) National Vital Statistics Report 50(6):17-18
26. Kanis JA, Oden A, Johnell O et al (2003) The components of excess mortality after hip fracture. Bone 32(5):468-473
27. Johnell O, Kanis JA, Oden A et al (2004) Mortality after osteoporotic fractures. Osteoporos Int 15(1):38-42
28. Kanis JA, Johnell O, Oden A et al (2004) The risk and burden of vertebral fractures in Sweden. Osteoporos Int 15(1):20-26. Jan
29. Drug Topics 2001 Red Book (2001) Montvale, Medical Economics Co, New Jersey
30. Gabriel SE, Tosteson AN, Leibson CL et al (2002) Direct medical costs attributable to osteoporotic fractures. Osteoporos Int 13(4):323-330
31. Centers for Medicare and Medicaid Services. Available at: http://cms.hhs.gov/providers/pufdownload/rvudown.asp. Accessed August 12, 2003
32. Leibson CL, Tosteson AN, Gabriel SE et al (2002) Mortality, disability, and nursing home use for persons with and without hip fracture: a population-based study. J Am Geriatr Soc 50(10):1644-1650
33. Agency for Healthcare Research and Quality. Medical Expenditure Panel Survey. Available at: http://www.meps.ahrq.gov/. Accessed August 12, 2003
34. Meerding WJ, Looman CW, Essink-Bot ML et al (2004) Distribution and determinants of health and work status in a comprehensive population of injury patients. J Trauma 56(1):150-161
35. U.S. Census Bureau, Bureau of Labor Statistics. CPS Annual Demographic Survey. Available at: http://ferret.bls.census.gov/macro/032002/perinc/ new05_000.htm. Accessed May 28, 2004
36. U.S. Census Bureau. Workforce Participation Rates. Available at: http://factfinder.census.gov/home/saff/main.html?_lang=en. Accessed May 28, 2004
37. Oleksik A, Lips P, Dawson A et al (2000) Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures. J Bone Miner Res 15(7):1384-1392
38. Nevitt MC, Ettinger B, Black DM et al (1998) The association of radiographically detected vertebral fractures with back pain and function: a prospective study. Ann Intern Med 128(10):793-800
39. Huang C, Ross PD, Wasnich RD (1996) Vertebral fracture and other predictors of physical impairment and health care utilization. Arch Intern Med 156(21):2469-2475
40. Tosteson AN, Gabriel SE, Grove MR et al (2001) Impact of hip and vertebral fractures on quality-adjusted life years. Osteoporos Int 12(12):1042-1049
41. Melton LJ, Chrischilles EA, Cooper C et al (1992) Perspective: how many women have osteoporosis? J Bone Miner Res 7:1005-1010
42. Schousboe JT, Ensrud KE, Nyman JA et al (2005) Potential cost-effective use of spine radiographs to detect vertebral deformity and select osteopenic post-menopausal women for amino-bisphosphonate therapy. Osteoporos Int 16(12):1883-1893
43. Bjarnason NH, Sarkar S, Duong T et al (2001) Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis. Osteoporos Int 12(11):922-930
44. Eastell R, Barton I, Hannon RA et al (2003) Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 18(6):1051-1056
45. Johannesson M, Meltzer D (1998) Some reflections on cost-effectiveness analysis. Health Economics 7:1-7
46. Ubel PA, Hirth RA, Chernew ME et al (2003) What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med 163(14):1637-1641
47. Macran S, Weatherly H, Kind P (2003) Measuring population health: a comparison of three generic health status measures. Med Care 41(2):218-231